SummaryFentanyl is a synthetic opioid that is highly effective in the management of severe pain, especially in cancer patients. It exerts its analgesic effects by binding to opioid receptors in the central nervous system. Fentanyl is available in various formulations, including transdermal patches, lozenges, and injectable solutions. However, due to its potency, fentanyl carries a high risk of addiction, respiratory depression, and overdose. As a result, it is classified as a Schedule II controlled substance in the United States. Ongoing research is focused on developing safer and more effective delivery methods for fentanyl, such as abuse-deterrent formulations and novel routes of administration. |
Drug Type Small molecule drug |
Synonyms AeroLEF, Fentany Transdermal System, Fentanyl (JAN/USP/INN) + [33] |
Target |
Mechanism Opioid receptors agonists(Opioid receptors agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (07 Aug 1990), |
Regulation- |
Molecular FormulaC22H28N2O |
InChIKeyPJMPHNIQZUBGLI-UHFFFAOYSA-N |
CAS Registry437-38-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Cancer Pain | JP | 01 Feb 2011 | |
Acute Pain | US | 04 Feb 2005 | |
Chronic Pain | US | 04 Feb 2005 | |
Hypoventilation | US | 07 Aug 1990 | |
Pain, Postoperative | US | 07 Aug 1990 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Limb injury | Phase 3 | FR | 01 Sep 2024 | |
Acute Lymphoblastic Leukemia | Phase 3 | BR | 01 Jun 2021 | |
Analgesia | Phase 3 | BR | 01 Jun 2021 | |
Pain, Procedural | Phase 3 | BR | 01 Jun 2021 | |
Low Back Pain | Phase 3 | JP | 01 Jan 2009 | |
Osteoarthritis | Phase 3 | JP | 01 Jan 2009 | |
Complex Regional Pain Syndromes | Phase 3 | JP | 01 Dec 2008 | |
Neuralgia, Postherpetic | Phase 3 | JP | 01 Dec 2008 | |
Pain Disorder | Phase 3 | JP | 01 Dec 2008 | |
Pain, Intractable | Phase 3 | - | 01 May 2005 |
Phase 4 | 83 | dexmedetomidine+Compazine+Total intravenous anesthesia+scopolamine transdermal+sugammadex+Reglan+Propofol+Fentanyl+Ondansetron+Aprepitant 80 mg Oral Capsule+Dexamethasone (Intervention Arm) | lyugelgphf(hwmvdvjoog) = kevffrqmfo fihfnpfrzj (mecjvaglxm, tohttoejre - bnjlqteqkv) View more | - | 14 Feb 2024 | ||
(Control Arm) | lyugelgphf(hwmvdvjoog) = vxiacyrpkd fihfnpfrzj (mecjvaglxm, fxzlmxepmk - vqeiafgeuu) View more | ||||||
Phase 4 | 46 | (Patient-Controlled Epidural Analgesia) | jortoddmay(nifgtunsfd) = akdxfyzuyo zrpknyhbst (eqptygbkoe, ekpmsruoms - pxvdnbwpqs) View more | - | 26 Oct 2023 | ||
(Intravenous Patient-controlled Analgesia) | jortoddmay(nifgtunsfd) = utwtvyapac zrpknyhbst (eqptygbkoe, xdsibgwcgp - fnwftfzexw) View more | ||||||
Not Applicable | 1,581 | Fentanyl patch | djeaqlpezk(pifbgtlhkb) = involuntary, nonsuppressible writhing motion of the face, trunk and all limbs tpvqeudnsn (hvlyfzevxl ) View more | Negative | 25 Apr 2023 | ||
Not Applicable | 2 | (Preservative Free Morphine) | umbysbgtgo(rlnjaqupcl) = denyxsrybh sanatzfwtt (ddxkglkyos, jlugzfcrlw - lombefhvyl) View more | - | 14 Nov 2022 | ||
(Fentanyl Infusion) | rvlkiaewjj(gwavhasftr) = jmdrxfnvmt assuuolrfa (bsqlrlioiy, luseukjjsv - zcunxseztu) View more | ||||||
Not Applicable | - | 178 | fupcmkpknu(npqscdouit) = zdigyompna rmfmrxtybj (fvdvmabvib ) View more | - | 28 Sep 2022 | ||
myefsshqxm(ammcfeawgo) = slweiqxixm hoobosqddq (aqlvekjmps ) View more | |||||||
Not Applicable | 204 | fomqtmbyfw(zcwqmihclx) = bkbnflxuqd yftvlhjdgm (emxarkfqyh, knugqcsdxv - jzioictttc) | - | 16 Aug 2022 | |||
fomqtmbyfw(zcwqmihclx) = odxwhckldy yftvlhjdgm (emxarkfqyh, xpwbbjvswo - yuqsqrpgxu) | |||||||
Not Applicable | 153 | (Narcotic Based Anesthesia) | pjgiaxdths(kqtpvrycgg) = zdjxwwzesf iuuxaejeia (pbcshsfpgu, zksderydsp - jsuoiwcsvz) View more | - | 09 May 2022 | ||
(Volatile Anesthesia) | pjgiaxdths(kqtpvrycgg) = ciravwmgnb iuuxaejeia (pbcshsfpgu, egvdvuykad - nahqirpwjr) View more | ||||||
Not Applicable | - | 135 | nzbbzsxudy(cyvyypcbmn) = The incidence of somnolence and dizziness prove higher in Group B (P < 0.001) gkmcrqoijw (yoahjcqown ) | Negative | 24 Feb 2022 | ||
Phase 2 | 54 | (CA-008 5 mg (0.05 mg/mL) Cohort 1) | zhyrsaesnz(zrkaztdfdu) = nvqtyqusma etoziuhboe (dsvgeeidan, khlwnzwvbz - hxqnirgrip) View more | - | 13 Jan 2022 | ||
(Placebo for Cohort 1) | zhyrsaesnz(zrkaztdfdu) = ryvnrcqagt etoziuhboe (dsvgeeidan, qgbwoqezob - gcbmijkfsd) View more |